Pradžia › Berkito limfoma › Merilendas
Berkito limfoma klinikiniai tyrimai Merilendas
11 tyrimai dėl Berkito limfoma ieško dalyvių vietose Merilendas.
Miestai Merilendas
Oficialus tyrimo tekstas (anglų kalba)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- Walter Reed National Military Medical Center, Bethesda
Renkami dalyviai2 fazė
366 Days – 46 Years · Visoms lytims · Atnaujinta 2026-10-02 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- University of Maryland/Greenebaum Cancer Center, Baltimore
Renkami dalyviai3 fazė
Amžius nuo 18 iki 39 · Visoms lytims · Atnaujinta 2026-10-02 · NCT03150693CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
- National Institutes of Health Clinical Center, Bethesda
Renkami dalyviai1/2 fazė
Amžius nuo 3 iki 39 · Visoms lytims · Atnaujinta 2026-09-30 · NCT05442515Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- National Institutes of Health Clinical Center, Bethesda
Renkami dalyviai1/2 fazė
Amžius nuo 18 iki 120 · Visoms lytims · Atnaujinta 2026-09-28 · NCT03223610Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Renkami dalyviai2 fazė
365 Days · Visoms lytims · Atnaujinta 2026-09-25 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Johns Hopkins Asthma & Allergy Center, Baltimore
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-21 · NCT07648264Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- University of Maryland, Baltimore
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-08 · NCT03666000A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Renkami dalyviai2 fazė
Amžius nuo 1 iki 30 · Visoms lytims · Atnaujinta 2026-09-01 · NCT04546399Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
- National Institutes of Health Clinical Center, Bethesda
Renkami dalyviai1 fazė
Amžius nuo 18 iki 120 · Visoms lytims · Atnaujinta 2026-08-25 · NCT05389423Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- ir dar 1
Renkami dalyviai3 fazė
365 Days – 25 Years · Visoms lytims · Atnaujinta 2026-08-25 · NCT03959085Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- University of Maryland, Baltimore
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-11-05 · NCT04260022Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.